Baker Bros. Advisors LP Cytom X Therapeutics, Inc. Transaction History
Baker Bros. Advisors LP
- $12.3 Billion
- Q3 2025
A detailed history of Baker Bros. Advisors LP transactions in Cytom X Therapeutics, Inc. stock. As of the latest transaction made, Baker Bros. Advisors LP holds 4,250,826 shares of CTMX stock, worth $16.4 Million. This represents 0.11% of its overall portfolio holdings.
Number of Shares
4,250,826
Previous 3,484,226
22.0%
Holding current value
$16.4 Million
Previous $7.91 Million
71.45%
% of portfolio
0.11%
Previous 0.08%
Shares
5 transactions
Others Institutions Holding CTMX
# of Institutions
110Shares Held
120MCall Options Held
1.49MPut Options Held
258K-
Vr Adviser, LLC New York, NY15.6MShares$60.1 Million7.54% of portfolio
-
Tang Capital Management LLC San Diego, CA11.1MShares$42.7 Million1.6% of portfolio
-
Perceptive Advisors LLC New York, NY9.68MShares$37.4 Million0.07% of portfolio
-
Vanguard Group Inc Valley Forge, PA8.95MShares$34.5 Million0.0% of portfolio
-
Orbimed Advisors LLC San Diego, CA8.46MShares$32.7 Million0.92% of portfolio
About CytomX Therapeutics, Inc.
- Ticker CTMX
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 65,950,200
- Market Cap $255M
- Description
- CytomX Therapeutics, Inc. operates as an oncology-focused biopharmaceutical company in the United States. The company develops antibody therapeutics based on its Probody technology platform for the treatment of cancer. The company's product candidates include CX-2009, an antibody drug conjugates (ADC) against CD166, which is in Phase II clinical...